Develops and markets pharmaceutical products. Licenses its technology to other pharmaceutical companies. Now — the numbers.
This is an established company with proven profits.
Average growth of 176% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $313K. In times of high interest rates, a gap like that can squeeze a company.
The market pays 30.1× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 176% a year on average.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.